Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer PR Newswire (Press Release) 2h
Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III Nsclc: results of phase III advance trial and real-world validation Nature.com 2d
Flaura2 Phase III Clinical Study Shows Overall Survival Benefit Trend Consistent with Global Data in Chinese Population Treated with Tagrisso and Chemotherapy for EGFR Mutant Advanced Non-Small Cell Lung Cancer China Money Network 4d
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate PR Newswire (Press Release) 5d
Ivonescimab topped Keytruda on median lung cancer survival by eight months in China but lacks U.S. Approval Medical Daily 5d Cancer China Global Health All sources
MRI surveillance alone improves outcomes for patients with small-cell lung cancer News-Medical.Net 7d Cancer Global Health Health All sources
AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer PMLiVE 13:01 Mon, 14 Sep AstraZeneca Cancer Pharma All sources
BioNTech and OncoC4 report median OS data from reserve-003 Phase III trial Clinical Trials Arena 7d BioNTech Pharma Biotech All sources
